HIV Cure Status 2024: Remission Cases, Gene Therapy & Ongoing Research

No scalable cure exists, but remarkable progress defines the landscape.

Current Standard: ART

  • Combination antiretroviral therapy (ART) suppresses HIV to undetectable (<50 copies/mL).
  • U=U: Undetectable = Untransmittable (sexual transmission).
  • Life expectancy near-normal with early, sustained treatment.
  • Long-acting injectables (cabotegravir/rilpivirine q2mo) improve adherence.

Documented Remission Cases (Not Scalable Cures)

  • Berlin Patient (Timothy Ray Brown): CCR5Δ32/Δ32 stem cell transplant for AML. Cured HIV; died 2020 from leukemia relapse.
  • London Patient (Adam Castillejo): Similar transplant; in remission since 2019.
  • Düsseldorf, New York, City of Hope patients: Additional CCR5Δ32 transplants with sustained remission.
  • Mississippi Baby / Visconti Cohort: Early ART → post-treatment control (not eradication).

Active Cure Strategies

Challenges

  • Reservoir heterogeneity (sanctuary sites: CNS, lymphoid, gut).
  • Immune exhaustion, viral diversity.
  • Safety of gene editing, conditioning toxicity.
  • Global scalability & cost.

Cure research is robustly funded (NIH Martin Delaney Collaboratories, IAS, amfAR). Goal: durable ART-free remission for all.

HIV & AIDS - Related Articles

Health Sciences © https://www.222health.com

StrategyMechanismStatus
"Shock & Kill" (Latency reversal)LRAs (HDACi, PKC agonists) reactivate reservoir → immune clearancePhase I/II; limited reservoir reduction
"Block & Lock" (Deep latency)Tat inhibitors, epigenetic silencers → permanent silencingPreclinical
Gene editing (CRISPR/Cas9)Excise provirus, CCR5 knockoutAnimal models; early human trials (EBT-101)
Broadly neutralizing antibodies (bNAbs)Target conserved Env epitopes; Fc-mediated clearancePhase II; some post-ART control
Therapeutic vaccinesBoost HIV-specific T/B cell responsesMultiple Phase I/II; modest immunogenicity
Stem cell / CAR-TEngineered HIV-resistant hematopoiesisPreclinical/early phase